From MS to NMOSD to early Alzheimer's disease, neurologic mAbs are delivering proven clinical benefit. But as efficacy becomes less of a differentiator, what determines whether these therapies reach patients? In this art...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Irish pharma group ICON carried out trial of Pfizer-BioNTech vaccine
The Irish Times discusses how ICON carried out the Pfizer-BioNTech vaccine trials.
-
Pfizer COVID vaccine trial proved remote monitoring, other innovations work, ICON CEO says
ICON CEO Steve Cutler discusses how the Pfizer COVID vaccine trial proves that starting clinical trials in weeks, as opposed to months, should be possible post-pandemic.
-
The impact of influenza vaccination on the COVID-19 pandemic? Evidence and lessons for public health policies
ICON's Richard Pitman joins global public health experts to address the importance of flu vaccination programs amid the COVID-19 pandemic.
-
Treatment options for Clostridioides difficile
This thought leadership article explores the increase in antimicrobial-resistant infections such as C diff due to the high volume of patients being treated in hosipitals for COVID-19.
This article is taken from European Biopharmaceutical Review October 2020, pages 12-14. Samedan Ltd.
-
Best Practices in Seasonal Vaccine Efficacy Studies: Tips for Successful Planning and Execution
A thought leadership piece by Cindy Dukes exploring the unique challenges in planning and executing a seasonal vaccine study.
